A new model, TxGNN, revolutionizes zero-shot drug repurposing by predicting treatments for diseases with no known therapies, offering improved accuracy and trust via interpretable AI explanations.
Atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights | Psychedelic Invest
Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA